Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Assets: 2012-2025

Historic Assets for Ascendis Pharma A (ASND) over the last 11 years, with Sep 2025 value amounting to $1.3 billion.

  • Ascendis Pharma A's Assets rose 12.38% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 12.38%. This contributed to the annual value of $1.3 billion for FY2024, which is 43.72% up from last year.
  • Ascendis Pharma A's Assets amounted to $1.3 billion in Q3 2025, which was up 9.62% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Assets ranged from a high of $1.5 billion in Q1 2022 and a low of $816.6 million during Q2 2024.
  • Moreover, its 3-year median value for Assets was $1.0 billion (2023), whereas its average is $1.1 billion.
  • Its Assets has fluctuated over the past 5 years, first spiked by 69.74% in 2021, then tumbled by 36.64% in 2023.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Assets stood at $1.2 billion in 2021, then dropped by 10.42% to $1.1 billion in 2022, then dropped by 20.10% to $888.3 million in 2023, then soared by 41.89% to $1.3 billion in 2024, then climbed by 12.38% to $1.3 billion in 2025.
  • Its Assets was $1.3 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.1 billion in Q1 2025.